Long-term safety of benoxaprofen.
Adverse experiences were monitored in 1,681 patients with rheumatoid arthritis (RA) or osteoarthritis to evaluate the safety of benoxaprofen at daily doses up to 1,000 mg during long-term therapy. Gastrointestinal side effects with benoxaprofen compared favorably to those reported during aspirin and ibuprofen therapy, with peptic ulcers reported in 0.4% of the patients or 1 ulcer for 200 patient years. The incidence of photosensitivity or onycholysis was 9%. Laboratory examinations revealed no significant changes in BUN, hematocrit, hemoglobin, SGOT, and SGPT values. The only trend toward abnormal values was seen in the LDH in patients with RA.